Follow
Univ. Prof. Dr. Andreas Zirlik
Univ. Prof. Dr. Andreas Zirlik
Head of Dept. of Cardiology, Chairman of the University Heart Center Graz, Medical University Graz
Verified email at medunigraz.at
Title
Cited by
Cited by
Year
Metformin inhibits proinflammatory responses and nuclear factor-κB in human vascular wall cells
K Isoda, JL Young, A Zirlik, LA MacFarlane, N Tsuboi, N Gerdes, ...
Arteriosclerosis, thrombosis, and vascular biology 26 (3), 611-617, 2006
6642006
Ly-6Chigh Monocytes Depend on Nr4a1 to Balance Both Inflammatory and Reparative Phases in the Infarcted Myocardium
I Hilgendorf, LMS Gerhardt, TC Tan, C Winter, TAW Holderried, ...
Circulation research 114 (10), 1611-1622, 2014
5502014
Atlas of the immune cell repertoire in mouse atherosclerosis defined by single-cell RNA-sequencing and mass cytometry
H Winkels, E Ehinger, M Vassallo, K Buscher, HQ Dinh, K Kobiyama, ...
Circulation research 122 (12), 1675-1688, 2018
4362018
CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1
A Zirlik, C Maier, N Gerdes, L MacFarlane, J Soosairajah, U Bavendiek, ...
Circulation 115 (12), 1571-1580, 2007
2802007
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY …
KK Ray, HM Colhoun, M Szarek, M Baccara-Dinet, DL Bhatt, VA Bittner, ...
The lancet Diabetes & endocrinology 7 (8), 618-628, 2019
2422019
First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension
M Böhm, F Mahfoud, C Ukena, UC Hoppe, K Narkiewicz, M Negoita, ...
Hypertension 65 (4), 766-774, 2015
2312015
Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial
M Szarek, HD White, GG Schwartz, M Alings, DL Bhatt, VA Bittner, ...
Journal of the American College of Cardiology 73 (4), 387-396, 2019
1832019
Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study
A Zirlik, SM Abdullah, N Gerdes, L MacFarlane, U Schönbeck, A Khera, ...
Arteriosclerosis, thrombosis, and vascular biology 27 (9), 2043-2049, 2007
1662007
Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation
A Zirlik, C Bode
Journal of thrombosis and thrombolysis 43 (3), 365-379, 2017
1452017
Innate response activator B cells aggravate atherosclerosis by stimulating T helper-1 adaptive immunity
I Hilgendorf, I Theurl, LMS Gerhardt, CS Robbins, GF Weber, A Gonen, ...
Circulation 129 (16), 1677-1687, 2014
1392014
Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial
SJ Shah, BA Borlaug, ES Chung, DE Cutlip, P Debonnaire, PS Fail, ...
The Lancet 399 (10330), 1130-1140, 2022
1332022
TRAF-1,-2,-3,-5, and-6 are induced in atherosclerotic plaques and differentially mediate proinflammatory functions of CD40L in endothelial cells
A Zirlik, U Bavendiek, P Libby, L MacFarlane, N Gerdes, J Jagielska, ...
Arteriosclerosis, thrombosis, and vascular biology 27 (5), 1101-1107, 2007
1292007
Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: results from the Dallas Heart Study
JA de Lemos, A Zirlik, U Schönbeck, N Varo, SA Murphy, A Khera, ...
Arteriosclerosis, thrombosis, and vascular biology 25 (10), 2192-2196, 2005
1292005
Nicotinamide for the treatment of heart failure with preserved ejection fraction
M Abdellatif, V Trummer-Herbst, F Koser, S Durand, R Adão, ...
Science translational medicine 13 (580), eabd7064, 2021
1252021
Pathogenic Autoimmunity in Atherosclerosis Evolves From Initially Protective Apolipoprotein B100–Reactive CD4+ T-Regulatory Cells
D Wolf, T Gerhardt, H Winkels, NA Michel, AB Pramod, Y Ghosheh, ...
Circulation 142 (13), 1279-1293, 2020
1162020
Binding of CD40L to Mac-1's I-domain involves the EQLKKSKTL motif and mediates leukocyte recruitment and atherosclerosis—but does not affect immunity and thrombosis in mice
D Wolf, JD Hohmann, A Wiedemann, K Bledzka, H Blankenbach, ...
Circulation research 109 (11), 1269-1279, 2011
1152011
Empagliflozin in acute myocardial infarction: the EMMY trial
D von Lewinski, E Kolesnik, NJ Tripolt, PN Pferschy, M Benedikt, ...
European heart journal 43 (41), 4421-4432, 2022
1142022
CD40L and its receptors in atherothrombosis—an update
NA Michel, A Zirlik, D Wolf
Frontiers in cardiovascular medicine 4, 40, 2017
1142017
Renal denervation in high-risk patients with hypertension
F Mahfoud, G Mancia, R Schmieder, K Narkiewicz, L Ruilope, M Schlaich, ...
Journal of the American College of Cardiology 75 (23), 2879-2888, 2020
1042020
A ligand-specific blockade of the integrin Mac-1 selectively targets pathologic inflammation while maintaining protective host-defense
D Wolf, N Anto-Michel, H Blankenbach, A Wiedemann, K Buscher, ...
Nature communications 9 (1), 525, 2018
922018
The system can't perform the operation now. Try again later.
Articles 1–20